PROVETOP

PE-Labeled Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein

Catalog No: KRASWT-HP012

Species
Human
Expression System
HEK293
Tag
His, Avi

Product overview

Recombinant PE-Labeled Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. PE-labeled Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer is assembled by biotinylated monomer and PE-Labeled streptavidin. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide (accession: AAV53343.1(HLA-A*11:01) & P61769(B2M) &VVVGAGGVGK).

Product Details

Molecular Aliases
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
Protein Length
Gly25-Thr305
Expression System
HEK293
Buffer / Formulation
Supplied as 0.22 μm filtered solution in PBS, 0.2% BSA (pH 7.4).
State
Liquid
Storage Conditions
Valid for 6 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.

References

  1. (1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support